West Pharmaceutical Services' (WST) has shown mixed performance according to the recent news updates. Despite some reports indicating the company's stock underperformance compared to its competitors on several instances, WST remains a favorite for certain financial entities. Various companies like Rafferty Asset Management LLC, Northern Trust Corp and Crossmark Global Holdings Inc. have been reported to liquidate their holdings in WST. Conversely, other entities such as Cibc World Markets Corp, CWA Asset Management Group LLC and Epoch Investment Partners Inc. have elevated their holdings in WST. Annual earnings have exceeded expectations, helping the company's stocks to bounce back in Q1. Even though WST has been cited to lag in earning growth rates, it has still been dubbed an attractive bet and a solid choice for long-term investors. The company has recorded successful Q4 and Q1, but forecasts suggest weak annual results. West Pharmaceutical has launched its Daikyo Crystal Zenith® (CZ) Ready-to-Use Nested Vials. Recent actions such as FDA 510(k) clearance for a new admixture device and insider selling of stocks have also been reported.
West Pharmaceutical Services WST News Analytics from Thu, 27 Jul 2023 07:00:00 GMT to Sun, 09 Jun 2024 17:14:32 GMT -
Rating 1
- Innovation 0
- Information 7
- Rumor -5
